Possible Interaction: Ellagic Acid and Doxorubicin Hydrochloride

“CONCLUSION We discovered that EA synergistically potentiated DOX and DDP in suppressing HCC with significantly reduced side effects and this may represent a novel strategy in HCC therapies with both high anticancer efficiencies and low systemic toxicity in patients.”

“ CONCLUSION We discovered that EA synergistically potentiated DOX and DDP in suppressing HCC with significantly reduced side effects and this may represent a novel strategy in HCC therapies with both high anticancer efficiencies and low systemic toxicity in patients.”

“RESULTS EA could both markedly potentiate anticancer activities of DOX and DDP to HCC HepG2 and SMMC-7721 cells, and reduce their cytotoxicity to normal liver HL-7702 cells.”

“ RESULTS EA could both markedly potentiate anticancer activities of DOX and DDP to HCC HepG2 and SMMC-7721 cells, and reduce their cytotoxicity to normal liver HL-7702 cells.”

“Interestingly, mitochondrial associated Bnip3 in cells treated with doxorubicin was markedly reduced by EA.”

“ Ellagic acid dose-dependently lowered caspase-3 activity and … 1 % declined activity and protein level of NF-κB. Doxorubicin treatment also up-regulated cardiac expression of p-p38, p-ERK 1/2 and p-… 1 % suppressed p-p38 expression and at 1 % down-regulated p-ERK 1/2 expression.”

“These findings suggest that ellagic acid is a potent cardiac protective agent against doxorubicin.”